Vanguard €pean Stk Idx Ins Pl € Acc

Performance History31/10/2024
Growth of 1,000 (EUR)
Vanguard €pean Stk Idx Ins Pl € Acc
Fund-3.125.5-9.216.28.3
+/-Cat-1.82.64.02.01.2
+/-Idx-0.20.10.50.30.1
 
Key Stats
NAV
05/11/2024
 EUR 216.49
Day Change 0.07%
Morningstar Category™ Europe Large-Cap Blend Equity
ISIN IE00BFPM9L96
Fund Size (Mil)
05/11/2024
 USD 4228.94
Share Class Size (Mil)
05/11/2024
 EUR 1423.41
Max Initial Charge -
Ongoing Charge
01/03/2024
  0.08%
Investment Objective: Vanguard €pean Stk Idx Ins Pl € Acc
The Fund seeks to provide long-term growth of capital by tracking the performance of the Index.
Returns
Trailing Returns (EUR)05/11/2024
YTD9.17
3 Years Annualised5.24
5 Years Annualised7.58
10 Years Annualised7.12
12 Month Yield 0.00
Management
Manager Name
Start Date
Not Disclosed
14/09/1998
Inception Date
06/12/2013
Advertisement
Benchmarks
Fund BenchmarkMorningstar Benchmark
MSCI Europe NR USDMorningstar DM Eur TME NR EUR
Target Market
Role In Portfolio
Standalone / CoreNot Specific
ComponentNot Specific
OtherNot Specific
Primary Objective
PreservationNo
GrowthYes
IncomeNot Specific
HedgingNot Specific
OtherNot Specific
Portfolio Profile for  Vanguard €pean Stk Idx Ins Pl € Acc30/09/2024
Morningstar Style Box®
Equity Style
Asset Allocation
  % Long% Short% Net Assets
Stocks99.550.0099.54
Bonds0.000.000.00
Cash0.120.010.11
Other0.370.020.35
Top 5 Regions%
Eurozone50.15
Europe - ex Euro27.35
United Kingdom21.73
United States0.74
Europe - Emerging0.03
Top 5 Sectors%
Financial Services18.43
Industrials17.12
Healthcare16.48
Consumer Defensive10.68
Consumer Cyclical8.88
Top 5 HoldingsSector%
Novo Nordisk AS Class BHealthcareHealthcare3.30
ASML Holding NVTechnologyTechnology2.90
Nestle SAConsumer DefensiveConsumer Defensive2.30
AstraZeneca PLCHealthcareHealthcare2.10
SAP SETechnologyTechnology2.07
Vanguard €pean Stk Idx Ins Pl € Acc

Related

In order to provide consistency across the report data provided by different Asset Managers, the calculated data points presented are generated using Morningstar’s proprietary calculation methodology which is set out in more detail at(https://www.morningstar.com/research/signature)
© Copyright 2024 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Cookie Settings        Disclosures